1. Global Initiative for Asthma (GINA), National Heart Lung and Blood Institute, National Institutes of Health . GINA report: Global strategy for asthma management and prevention (2020 report), https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf (accessed 25 May 2021).
Google Scholar2. Global Initiative for Chronic Obstructive Lung Disease (GOLD guideline) . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2020 report), https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf (accessed 25 May 2021).
Google Scholar3. Asthma . World Health Organization 2020, https://www.who.int/news-room/q-a-detail/asthma (accessed 25 May 2021).
Google Scholar4. Papi, A, Brightling, C, Pedersen, SE, et al Asthma. Lancet 2018; 391: 783–800.
Google Scholar | Crossref | Medline5. D’Amato, G, Vitale, C, Molino, A, et al Asthma-related deaths. Multidiscip Respir Med 2016; 11: 37.
Google Scholar | Crossref | Medline6. Chronic obstructive pulmonary disease (COPD) . World Health Organization 2020, https://www.who.int/health-topics/chronic-respiratory-diseases (accessed 25 May 2021).
Google Scholar7. GBD 2015 Chronic Respiratory Disease Collaborators . Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med 2017; 5: 691–706.
Google Scholar | Crossref | Medline8. Peters, SP, Ferguson, G, Deniz, Y, et al Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med 2006; 100: 1139–1151.
Google Scholar | Crossref | Medline | ISI9. Price, D, Fletcher, M, van der Molen, T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med 2014; 24: 14009.
Google Scholar | Crossref | Medline | ISI10. Slejko, JF, Ghushchyan, VH, Sucher, B, et al Asthma control in the United States, 2008-2010: indicators of poor asthma control. J Allergy Clin Immunol 2014; 133: 1579–1587.
Google Scholar | Crossref | Medline | ISI11. Boulet, L-P, Vervloet, D, Magar, Y, et al Adherence: the goal to control asthma. Clin Chest Med 2012; 33: 405–417.
Google Scholar | Crossref | Medline12. Molimard, M, Gros, V Le. Impact of patient-related factors on asthma control. J Asthma 2008; 45: 109–113.
Google Scholar | Crossref | Medline | ISI13. Melani, AS, Bonavia, M, Cilenti, V, et al Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011; 105: 930–938.
Google Scholar | Crossref | Medline | ISI14. Al-Jahdali, H, Ahmed, A, Al-Harbi, A, et al Improper inhaler technique is associated with poor asthma control and frequent emergency department visits. Allergy Asthma Clin Immunol 2013; 9: 8.
Google Scholar | Crossref | Medline15. Arora, P, Kumar, L, Vohra, V, et al Evaluating the technique of using inhalation device in COPD and bronchial asthma patients. Respir Med 2014; 108: 992–998.
Google Scholar | Crossref | Medline | ISI16. Bateman, ED, Boushey, HA, Bousquet, J, et al Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med 2004; 170: 836–844.
Google Scholar | Crossref | Medline | ISI17. Stempel, DA, Raphiou, IH, Kral, KM, et al Serious asthma events with fluticasone plus salmeterol versus fluticasone alone. N Engl J Med 2016; 374: 1822–1830.
Google Scholar | Crossref | Medline18. Stockley, RA, Chopra, N, Rice, L. Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax 2006; 61: 122–128.
Google Scholar | Crossref | Medline19. Calverley, PMA, Anderson, JA, Celli, B, et al Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775–789.
Google Scholar | Crossref | Medline | ISI20. Lavorini, F, Janson, C, Braido, F, et al What to consider before prescribing inhaled medications: a pragmatic approach for evaluating the current inhaler landscape. Ther Adv Respir Dis 2019; 13: 1753466619884532.
Google Scholar | SAGE Journals | ISI21. Virchow, JC, Crompton, GK, Dal Negro, R, et al Importance of inhaler devices in the management of airway disease. Respir Med 2008; 102: 10–19.
Google Scholar | Crossref | Medline | ISI22. Melani, AS, Paleari, D. Maintaining control of chronic obstructive airway disease: adherence to inhaled therapy and risks and benefits of switching devices. COPD 2016; 13: 241–250.
Google Scholar | Crossref | Medline23. Shimizu, Y, Shiobara, T, Arai, R, et al Real-life effectiveness of fluticasone furoate/vilanterol after switching from fluticasone/salmeterol or budesonide/formoterol therapy in patients with symptomatic asthma: Relvar Ellipta for Real Asthma Control Study (RERACS study). J Thorac Dis 2020;12: 1877–1883.
Google Scholar | Crossref | Medline24. Bloom, CI, Douglas, I, Olney, J, et al Cost saving of switching to equivalent inhalers and its effect on health outcomes. Thorax 2019; 74: 1078–1086.
Google Scholar | Crossref | Medline25. Wilkinson, AJK, Braggins, R, Steinbach, I, et al Costs of switching to low global warming potential inhalers. An economic and carbon footprint analysis of NHS prescription data in England. BMJ Open 2019; 9: e028763.
Google Scholar | Crossref | Medline26. UN Environment . Montreal protocol on substances that deplete the ozone layer. Medical and Chemicals Technical Options Committee, 2018 Assessment Report, UN Environment, United Nations Environment Programme, Nairobi, Kenya, 2018.
Google Scholar27. Price, D, Thomas, V, von Ziegenweidt, J, et al Switching patients from other inhaled corticosteroid devices to the Easyhaler®: historical, matched-cohort study of real-life asthma patients. J Asthma Allergy 2014; 7: 31–51.
Google Scholar | Medline28. Tamási, L, Szilasi, M, Gálffy, G. Clinical effectiveness of budesonide/formoterol fumarate Easyhaler for patients with poorly controlled obstructive airway disease: a real-world study of patient-reported outcomes. Adv Ther 2018; 35: 1140–1152.
Google Scholar | Crossref | Medline29. Gálffy, G, Mezei, G, Németh, G, et al Inhaler competence and patient satisfaction with Easyhaler: results of two real-life multicentre studies in asthma and COPD. Drugs R D 2013; 13: 215–222.
Google Scholar | Crossref | Medline30. Sherman, RE, Anderson, SA, Dal Pan, GJ, et al Real-world evidence — what is it and what can it tell us? N Engl J Med 2016; 375: 2293–2297.
Google Scholar | Crossref | Medline31. Thomas, M, Kay, S, Pike, J, et al The Asthma Control Test (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey. Prim Care Respir J 2009; 18: 41–49.
Google Scholar | Crossref | Medline32. Schatz, M, Kosinski, M, Yarlas, AS, et al The minimally important difference of the asthma control test. J Allergy Clin Immunol 2009; 124: 719–723.e1.
Google Scholar | Crossref33. Jones, PW, Harding, G, Berry, P, et al Development and first validation of the COPD assessment Test. Eur Respir J 2009; 34: 648–654.
Google Scholar | Crossref | Medline | ISI34. Juniper, EF, Guyatt, GH, Cox, FM, et al Development and validation of the mini asthma quality of life questionnaire. Eur Respir J 1999; 14: 32–38.
Google Scholar | Crossref | Medline | ISI35. Mahler, DA, Wells, CK. Evaluation of clinical methods for rating dyspnea. Chest 1988; 93: 580–586.
Google Scholar | Crossref | Medline | ISI36. Quanjer, PH, Stanojevic, S, Cole, TJ, et al Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J 2012; 40: 1324–1343.
Google Scholar | Crossref | Medline | ISI37. Perpiñá Tordera, M, Viejo, JL, Sanchis, J, et al Assessment of patient satisfaction and preferences with inhalers in asthma with the FSI-10 Questionnaire. Arch Bronconeumol 2008; 44: 346–352.
Google Scholar | Crossref | Medline38. Syk, J, Vinge, I, Sörberg, M, et al A multicenter, observational, prospective study of the effectiveness of switching from Budesonide/Formoterol Turbuhaler® to Budesonide/Formoterol Easyhaler. Adv Ther 2019; 36: 1756–1769.
Google Scholar | Crossref | Medline39. Park, SY, Yoon, SY, Shin, B, et al Clinical factors affecting discrepant correlation between asthma control test score and pulmonary function. Allergy Asthma Immunol Res 2015; 7: 83–87.
Google Scholar | Crossref | Medline40. Kirjavainen, M, Mattila, L, Vahteristo, M, et al Pharmacokinetics of salmeterol and fluticasone propionate delivered in combination via Easyhaler and diskus dry powder inhalers in healthy subjects. J Aerosol Med Pulm Drug Deliv 2018; 31: 290–297.
Google Scholar | Crossref | Medline41. Jõgi, R, Lähelmä, S, Vahteristo, M, et al In vitro flow rate dependency of delivered dose and fine particle dose of salmeterol/fluticasone propionate Easyhaler and seretide diskus with patient flow rates collected in a randomized controlled trial. J Aerosol Med Pulm Drug Deliv 2019; 32: 88–98.
Google Scholar | Crossref | Medline42. Anderson, P. Patient preference for and satisfaction with inhaler devices. Eur Respir Rev 2005; 14: 109 LP–116LP.
Google Scholar | Crossref43. Ahonen, A, Leinonen, M, Ranki-Pesonen, M. Patient satisfaction with Easyhaler compared with other inhalation systems in the treatment of asthma: a meta-analysis. Curr Ther Res 2000; 61: 61–73.
Google Scholar | Crossref44. Nieminen, MM, Vidgren, P, Kokkarinen, J, et al A new beclomethasone dipropionate multidose powder inhaler in the treatment of bronchial asthma. Respiration 1998; 65: 275–281.
Google Scholar | Crossref | Medline45. Giner, J, Torrejón, M, Ramos, A, et al Patient preference in the choice of dry powder inhalers. Arch Bronconeumol 2004; 40: 106–109.
Google Scholar | Crossref | Medline46. Vanto, T, Hämäläinen, KM, Vahteristo, M, et al Comparison of two budesonide dry powder inhalers in the treatment of asthma in children. J Aerosol Med 2004; 17: 15–24.
Google Scholar | Crossref | Medline47. Kirby, S, Falcoz, C, Daniel, MJ, et al Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. Eur J Clin Pharmacol 2001; 56: 781–791.
Google Scholar | Crossref | Medline